Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL (Pona-CELL)
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia
Sponsor: CZECRIN - Czech Clinical Research Infrastructure Network
Terminated
slower recruitment rate;
This PHASE2 trial investigates Acute Lymphoblastic Leukemia, Adult and Newly Diagnosed and is currently terminated or withdrawn. CZECRIN - Czech Clinical Research Infrastructure Network leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Suspended PHASE2
Status: Active Not Recruiting → Suspended
-
Dec 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CZECRIN - Czech Clinical Research Infrastructure Network
- Institute of Hematology and Blood Transfusion, Czech Republic
For direct contact, visit the study record on ClinicalTrials.gov .